ARCHIVES

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

This article is from The Cancer Letter archive.

Vol. 29 No. 9 | September 29, 2006

Download PDF Visit The Full Archive

Related Articles

Virology Contract Phaseout To Cut $5 Million In FY 1980; Bigger reduction Coming In 1982

July 27, 1979

FDA Approves Velcade Injection In Mantle Cell Lymphoma

October 31, 2014

Volasertib and LDAC Doubled Response in Older Patients

July 25, 2014

More Clinical Trials Money Top Priority, DeVita Says; Drug Discovery Groups RFA Gets 12 Applications

February 24, 1984

Children of Male Cancer Survivors Have Highrt Risk of Birth Defects

February 25, 2011

Mayo Clinic Cancer Center Wins NCI Support Grant Renewal

June 19, 2009